Artivion, Inc. (NYSE:AORT) Expected to Post Quarterly Sales of $73.55 Million

Wall Street brokerages expect that Artivion, Inc. (NYSE:AORTGet Rating) will report $73.55 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Artivion’s earnings. The lowest sales estimate is $72.50 million and the highest is $74.60 million. Artivion reported sales of $71.09 million in the same quarter last year, which indicates a positive year over year growth rate of 3.5%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Artivion will report full year sales of $322.10 million for the current year, with estimates ranging from $322.00 million to $322.20 million. For the next financial year, analysts forecast that the business will post sales of $355.71 million, with estimates ranging from $350.12 million to $360.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Artivion.

Artivion (NYSE:AORTGet Rating) last issued its earnings results on Thursday, February 17th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.45). Artivion had a positive return on equity of 1.69% and a negative net margin of 4.96%. The firm had revenue of $79.39 million during the quarter, compared to the consensus estimate of $78.00 million.

AORT has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Artivion from a “sell” rating to a “hold” rating in a report on Wednesday, February 23rd. Stifel Nicolaus began coverage on shares of Artivion in a report on Thursday, March 3rd. They issued a “buy” rating and a $30.00 price target on the stock. TheStreet lowered Artivion from a “c-” rating to a “d” rating in a research report on Friday, February 18th. Finally, Needham & Company LLC lowered their price objective on Artivion from $39.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, February 18th.

NYSE:AORT traded down $1.22 during trading hours on Wednesday, hitting $20.96. The company had a trading volume of 229,293 shares, compared to its average volume of 192,017. The firm has a market cap of $842.17 million, a P/E ratio of -54.08 and a beta of 1.55. The company’s 50-day simple moving average is $19.77. Artivion has a 52 week low of $16.56 and a 52 week high of $32.34. The company has a quick ratio of 3.80, a current ratio of 5.51 and a debt-to-equity ratio of 1.04.

In other Artivion news, CEO James P. Mackin sold 10,639 shares of the business’s stock in a transaction dated Thursday, February 10th. The stock was sold at an average price of $17.86, for a total value of $190,012.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 10,638 shares of the business’s stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $17.30, for a total value of $184,037.40. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock.

About Artivion (Get Rating)

Artivion Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.

Featured Articles

Get a free copy of the Zacks research report on Artivion (AORT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.